VRNA Verona Pharma ADS

Verona Pharma to Present at Jefferies London Healthcare Conference

Verona Pharma to Present at Jefferies London Healthcare Conference

LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m. GMT.

A webcast of the event will be available on the Events and Presentations link on the Investors page of the Company’s website, .

For further information please contact:

Verona Pharma plcTel:
Victoria Stewart, Senior Director of Investor Relations and Communications
Argot Partners

(US Investor Enquiries)		Tel:

Ten Bridge Communications

International / US Media Enquiries		Tel:



Wendy Ryan 
 

About Verona Pharma

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. OhtuvayreTM (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit .



EN
05/11/2024

Underlying

VRNAVerona Pharma ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Verona Pharma ADS

Free Trial
VRNA Verona Pharma A...

Verona Pharma: 2 directors

Two Directors at Verona Pharma bought/maiden bought 10,155 shares at between 37.896USD and 38.390USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direc...

VRNA VERONA PHARMA ADS
1h / 10m 1h / 10m 1 EN
 PRESS RELEASE
Free
VRNA Verona Pharma A...

Verona Pharma to Present at Jefferies London Healthcare Conference

Verona Pharma to Present at Jefferies London Healthcare Conference LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m. GMT. A webcast of the event will be available on the Events and Presentations link on the Investors page of the Company’s website, . For further information please contact: Verona Pharma plcTel: Victoria Stewart, Senior Direct...

November 5, 2024 1 EN
 PRESS RELEASE
Free
VRNA Verona Pharma A...

Verona Pharma Reports Third Quarter 2024 Financial Results and Provide...

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled across a broad COPD population Pipeline expansion continues: Phase 2 programs enrolling Conference call today at 9:00 a.m. ET / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focuse...

November 4, 2024 1 EN
 PRESS RELEASE
Free
VRNA Verona Pharma A...

Verona Pharma to Report Third Quarter 2024 Financial Results and Provi...

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. GMT to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: ...

October 21, 2024 1 EN
 PRESS RELEASE
Free
VRNA Verona Pharma A...

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies i...

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024 Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD population LONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces four oral presentations and two posters on analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (“COPD”) will be presented at CHEST Annual Meet...

September 30, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch